Citations

A comparison of the biochemical, mechanical, and bioactive properties of a porcine myocardial matrix to a new human myocardial matrix and the feasibility of translating this allogeneic hydrogel to the clinic.

AbstractAlzheimer's disease is the public health crisis of the 21st century. There is a clear need for a widely available, inexpensive and reliable method to diagnosis Alzheimer's disease in the earliest stages, track disease progression, and accelerate clinical development of new therapeutics. One avenue of research being explored is blood based biomarkers. In April 2012, the Alzheimer's Association and the Alzheimer's Drug Discovery Foundation convened top scientists from around the world to discuss the state of blood based biomarker development. This manuscript summarizes the meeting and the resultant discussion, including potential next steps to move this area of research forward.

SummaryLaboratory (LTLS) and clinical (CTLS) tumour lysis syndrome (TLS) are frequent complications in newly diagnosed children with advanced mature B cell non‐Hodgkin lymphoma (B‐NHL). Rasburicase, compared to allopurinol, results in more rapid reduction of uric acid in paediatric patients at risk for TLS. However, the safety and efficacy of rasburicase for the treatment or or prevention of TLS has not been prospectively evaluated. Children with newly diagnosed stage III‐IV, bone marrow+ and/or central nervous system+ mature B‐NHL received hydration and rasburicase prior to cytoreductive therapy. Rasburicase was safe and well‐tolerated and there were no grade III–IV toxicities probably or directly related to rasburicase. Patients with an initial lactate dehydrogenase ≥2× upper limit of normal had a significantly elevated uric acid level (P = 0·005), increased incidence of TLS (P−0·005) and lower glomerular filtration rate (GFR; P < 0·001). Following rasburicase, there was only a 9% and 5% incidence of LTLS and CTLS, respectively. Furthermore, there was a significant improvement in estimated GFR from Day 0 to Day 7 following rasburicase (P = 0·0007) and only 1·3% of patients required new onset renal assisted support after rasburicase administration. A TLS strategy incorporating rasburicase prior to cytoreductive chemotherapy proved safe and effective in preventing new onset renal failure and was associated with a significant improvement in GFR.

SummaryBackgroundCompensatory hyperhidrosis due to the treatment for focal primary hyperhidrosis can be devastating and life‐altering.ObjectiveThe purpose of this paper is to discuss use of the iodine starch test and dilute botulinum toxin to decrease compensatory hyperhidrosis over large surface areas.MethodsA large area of the trunk affected by compensatory hyperhidrosis was treated with dilute botulinum toxin therapy using a starch iodine test for localization.ResultsThe patient had exceptional results with his compensatory truncal sweating returning to normal and remaining stable for multiple months.ConclusionTreating compensatory hyperhidrosis of large surface areas with dilute botulinum toxin therapy is effective and safe.